Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011;22:391-420.

Department of Core Clinical Pathology & Biochemistry, PathWest Royal Perth Hospital, Perth, WA 6000, Australia.
The Clinical biochemist. Reviews / Australian Association of Clinical Biochemists 02/2011; 32(1):45-7.
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low bone mineral density (BMD) is a strong risk factor for low trauma fractures in the postmenopausal population without known chronic kidney disease (CKD). In stage 1–3 CKD, low BMD can also be used to predict fracture risk with the gradient of risk similar to patients without CKD even though patients with stage 3 CKD have an approximate doubling of risk compared with age-matched patients without CKD. This greater risk of fracture in stage 3 CKD is not calculated in the current FRAX model. In stage 4–5 CKD, BMD by dual-energy x-ray absorptiometry (DXA) is a poor predictor of fracture risk probably related to the severe derangements in bone metabolism in severe CKD, which alter bone quality and strength not measured by DXA. Serial BMD by DXA, however, may be useful in all stages of CKD to monitor for potential loss of BMD or effect of pharmacological agents to improve BMD. Newer radiological technologies, particularly high-resolution peripheral quantitative computerized tomography (HRpQcT) of the radius and tibia show promise to define the microstructural changes in bone that explain the greater risk of fracture observed in patients with CKD versus patients without CKD. BMD by DXA may still be of value across the spectrum of CKD, but physicians should realize its limitations and understand the greater risk of fracture in patients in all stages of CKD as compared to age-matched and BMD-matched patients without CKD.
    Clinical Reviews in Bone and Mineral Metabolism 09/2012; 10(3). DOI:10.1007/s12018-012-9130-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fragility fractures, and in particular those of the femoral neck, vertebrae, wrist and proximal humerus, are increasing, with a socio-economic impact strong enough to suggest modifications in their current management. These fractures are characterized by their time of event, clinical approach and functional results, which are also influenced by co-morbidity of the patient. However, in Italy, it was recently shown that patients hospitalized for hip fracture, as well as having an average age over 75, are averagely in their fourth fracturative episode. The high mortality rate usually associated to this type of fracture is significantly decreased when an anti-osteoporosis therapy is initiated. Given the increase of the elderly population in the coming years, and especially the octogenarians, it is necessary to implement a multidisciplinary therapeutic approach suitable to the recovery of a quality of life of the same level to the period preceding the fragility fracture. Therefore, during the first fragility fracture, the orthopedist is essential to implement an adjuvant drug therapy that promotes healing and begins to improve bone quality, with the aim of reducing the risk of further fractures.
    Archivio di Ortopedia e Reumatologia 12/2011; 122(3-4). DOI:10.1007/s10261-011-0035-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: The reference values for bone turnover markers (BTMs) have a significant role in the diagnosis, monitoring, and treatment of metabolic bone disease. This study proposes that the peak value of bone mineral density and the trough value for the BTM curve can be used to determine the reference range of BTM. The aim of this study is to determine the reference intervals of BTMs for adult females in China with an attempt to reference the peak bone mineral density (BMD) with the corresponding BTM valley. This study included 546 premenopausal and 394 postmenopausal women. The levels of several BTMs were determined, and the BMD was measured using a dual-energy X-ray absorptiometry. The BTMs of postmenopausal women were 17-96 % higher than premenopausal women. The change of BTM with age presented an optimal goodness-of-fit according to the cubic regression model (R (2) = 0.074-0.346, all P = 0.000). All kinds of BTM levels were positively correlated with age in premenopausal women aged 27-56 years old (r = 0.167-0.502, P = 0.023-0.000). Except for uCTX, the BTM reference value determined using a curve-fitting valley was significantly lower than the reference values for premenopausal women. The BTM reference values determined in this study were also significantly different from the reference values given by the manufacturers of the reagents used. This study found that the changes of level with age of BTMs in Chinese women present an optimal goodness-of-fit according to the cubic regression model. The fitting valley corresponds to the BMD fitting peak and may possibly be an effective means of determining the BTM reference intervals.
    Osteoporosis International 07/2013; DOI:10.1007/s00198-013-2439-x · 4.17 Impact Factor